Access DB# 84663

JAN

SEARCH REQUEST FORM

Scientific and Technical Inf rmation Center

Requester's Full Name: FONDA Examiner # : 71970 Date: 1-17-03

Art Unit: 1623 Phone Number 308-1620 Serial Number: 09/700879

Mail Box and Bldg/Room Location: _____ Results Format Preferred (circle): ~~PAPER~~ DISK E-MAIL

CM1 8B19 CM1 8405

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: see attached assignment sheet

Inventors (please provide full names): _____

Earliest Priority Filing Date: 5-19-99

***For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.**

Please search compositions comprising hyaluronic acid bonded to an agent for treating joint disease, as in claims 1-10, 12-14, and 18-21. Please also search preparative method of claim 11 and therapeutic methods of claims 17 and 22.

Thanks.
K.

RECEIVED
JAN 17 2003
TECH CENTER 1600/2900

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

****

STAFF USE ONLY	Type of Search		Vendors and cost where applicable	
Searcher: Jan	NA Sequence (#)		STN	✓
Searcher Phone #: 4498	AA Sequence (#)		Dialog	
Searcher Location:	Structure (#)	✓	Questel/Orbit	
Date Searcher Picked Up: 1/21/03	Bibliographic	✓	Dr.Link	
Date Completed: 1/24/03	Litigation		Lexis/Nexis	
Searcher Prep & Review Time:	Fulltext		Sequence Systems	✓
Clerical Prep Time: 15	Patent Family		WWW/Internet	
Online Time: +120	Other		Other (specify)	

PTO-1590 (8-01)

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

```
(FILE 'HOME' ENTERED AT 15:52:25 ON 21 JAN 2003)
          SET COST OFF

FILE 'REGISTRY' ENTERED AT 15:52:46 ON 21 JAN 2003
L1            2 S HYALURONIC ACID/CN OR 9067-32-7
L2          753 S ?HYALURON?/CNS NOT L1
L3          435 S L2 NOT SQL/FA
L4          318 S L2 NOT L3
              E CYCLOOXYGENASE/CN
L5            1 S E8
L6            2 S E3,E7
              E MATRIX METALLOPROTEASE/CN
L7           15 S E3,E5-E13,E15-E17,E23,E24
L8            5 S E25,E36,E43,E45,E46
L9            4 S E50,E51,E55,E58
L10           1 S E61
L11           5 S E72,E75,E79-E81
L12           4 S E85,E89-E91
L13        1365 S (?METALLOPROTEINASE? OR ?METALLOPROTEASE?)/CNS
L14           STR
L15          31 S L14 CSS
L16        2264 S L14 FUL
              SAV TEMP L16 FONDA700/A
L17         629 S L14 CSS FUL SUB=L16
              SAV L17 FONDA700A/A

FILE 'HCAPLUS' ENTERED AT 16:16:23 ON 21 JAN 2003
L18       10031 S L1
L19        3440 S L3
L20         151 S L4
L21       14614 S HYALURONIC ACID OR HYALURONATE OR HYALURONAN
L22       20161 S ?HYALURON?
L23       20696 S L18-L22
L24        1922 S L5
L25        9113 S L6
L26       13384 S (COX OR CYCLOOXYGENASE OR CYCLO OXYGENASE)(L)2 OR COX2
L27          13 S PROSTAGLANDIN(L)(ENDOPEROXIDASE OR ENDO PEROXIDASE)(L)(SYNTHA
L28          41 S L23 AND L24-L27
L29       26594 S L7-L13
L30         476 S L23 AND L29
L31         309 S L17
L32           4 S L23 AND L31

FILE 'REGISTRY' ENTERED AT 16:21:16 ON 21 JAN 2003
L33        1635 S L16 NOT L17

FILE 'HCAPLUS' ENTERED AT 16:21:22 ON 21 JAN 2003
L34           3 S L33 AND L23
L35          45 S L28,L32,L34
              E ANTIRHEUMAT/CT
              E E5+ALL
L36        4437 S E5,E4+NT
L37          48 S L23 AND L36
L38          91 S L35,L37
L39          77 S L23 AND (ANTIRHEUMAT? OR ANTI RHEUMAT?)
L40         136 S L38,L39
L41           6 S L40 AND ?CONJUGAT?
              E TAMURA T/AU
L42         596 S E3-E5
              E TAMURA TATSUYA/AU
```

=> d his

```
     (FILE 'REGISTRY' ENTERED AT 16:36:53 ON 27 JAN 2003)
                DEL HIS
L1                2 S HYALURONIC ACID/CN OR 9067-32-7
L2              773 S ?HYALURON?/CNS
                    ACT FONDA700A/A
                ---------
L3                  STR
L4   (         2264)SEA FILE=REGISTRY SSS FUL L3
L5               629 SEA FILE=REGISTRY SUB=L4 CSS FUL L3
                ---------

     FILE 'HCAPLUS' ENTERED AT 16:39:55 ON 27 JAN 2003
L6          10046 S L1
L7          12812 S L2
L8          14642 S HYALURONIC ACID OR HYALURONATE OR HYALURONAN
L9          20190 S ?HYALURON?
L10         20726 S L6-L9
L11           310 S L5
L12             4 S L11 AND L10

     FILE 'HCAPLUS' ENTERED AT 16:40:56 ON 27 JAN 2003
```

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 16:41:26 ON 27 JAN 2003

FILE COVERS 1907 - 27 Jan 2003 VOL 138 ISS 5
FILE LAST UPDATED: 26 Jan 2003 (20030126/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l12 all hitstr tot

L12 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:716020 HCAPLUS
DN 137:253053
TI Medical devices and compositions for treating vulnerable plaque
IN Brown, David L.
PA Volcano Therapeutics, Inc., USA
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 63-7 (Pharmaceuticals)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002072014	A2	20020919	WO 2002-US7244	20020308
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003004141	A1	20030102	US 2002-96131	20020308
PRAI	US 2001-274331P	P	20010308		

AB Medical devices, compns. and methods for treating or preventing atherosclerotic plaque rupture are disclosed. Specifically, medical devices that deliver to a treatment site metalloproteinase inhibitors (MMPI) are disclosed. The medical devices include catheters, guide wires, vascular stents, micro-particles, electronic leads, probes, sensors, drug depots, transdermal patches, and vascular patches. Representative MMPIs included zinc chelators, urea derivs., caprolactone-based inhibitors, phoshonamides, piperazines, sulfonamides, tertiary amines, carbamate derivs., mercapto alcs., mercapto ketones, antimicrobial tertracyclines, non-antimicrobial tetracyclines, and derivs. and combinations thereof. In one embodiment a self-expanding vascular stent is coated with at least one MMPI and deployed at a site within an artery where vulnerable plaque has been identified.

ST medical device plaque; polymer coating medical device plaque; drug delivery medical device plaque

IT Polyesters, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(caprolactone-based; medical devices and compns. for treating vulnerable plaque)

IT Medical goods
(catheters; medical devices and compns. for treating vulnerable plaque)

IT Drug delivery systems
(controlled-release; medical devices and compns. for treating vulnerable plaque)

IT Polyesters, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dilactone-based; medical devices and compns. for treating vulnerable plaque)

IT Polyesters, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxycarboxylic acid-based; medical devices and compns. for treating vulnerable plaque)

IT Polyesters, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lactic acid-based; medical devices and compns. for treating vulnerable plaque)

IT Cellophane
Coating materials
Electric contacts
Human
Medical goods
Sensors
(medical devices and compns. for treating vulnerable plaque)

IT Acrylic polymers, biological studies

Alkyd resins
Collagens, biological studies
Epoxy resins, biological studies
Fibrinogens
Fibrins
Fluoropolymers, biological studies
Polyamides, biological studies
Polyanhydrides
Polycarbonates, biological studies
Polyesters, biological studies
Polyethers, biological studies
Polyimides, biological studies
Polyolefins
Polyoxymethylenes, biological studies
Polyphosphazenes
Polysiloxanes, biological studies
Polyurethanes, biological studies
Rayon, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medical devices and compns. for treating vulnerable plaque)

IT Sulfonamides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medical devices and compns. for treating vulnerable plaque)

IT Alcohols, biological studies
Ketones, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mercapto; medical devices and compns. for treating vulnerable plaque)

IT Polyethers, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ortho ester group-contg.; medical devices and compns. for treating vulnerable plaque)

IT Tooth
(plaque; medical devices and compns. for treating vulnerable plaque)

IT Polyethers, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyester-; medical devices and compns. for treating vulnerable plaque)

IT Polyesters, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyether-; medical devices and compns. for treating vulnerable plaque)

IT Vinyl compounds, biological studies
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polymers; medical devices and compns. for treating vulnerable plaque)

IT Medical goods
(stents; medical devices and compns. for treating vulnerable plaque)

IT Amines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tertiary; medical devices and compns. for treating vulnerable plaque)

IT Drug delivery systems
(transdermal; medical devices and compns. for treating vulnerable plaque)

IT Medical goods
(wires; medical devices and compns. for treating vulnerable plaque)

IT 9001-12-1, Metalloproteinase-1
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; medical devices and compns. for treating vulnerable plaque)

IT 9002-85-1, Polyvinylidene chloride 9002-86-2, PVC 9003-09-2, Polyvinyl methyl ether 9003-20-7, Poly(vinyl acetate) 9003-53-6, Polystyrene 9003-54-7, Acrylonitrile-styrene copolymer 9003-56-9, Acrylonitrile-butadiene-styrene copolymer 9003-63-8, Poly(butyl methacrylate) 9004-32-4, Carboxymethyl cellulose 9004-34-6, Cellulose, biological studies 9004-35-7, Cellulose acetate 9004-36-8, Cellulose acetate butyrate 9004-48-2, Cellulose propionate **9004-61-9**, **Hyaluronic acid** 9004-70-0, Cellulose nitrate 9005-25-8, Starch, biological studies 9015-12-7, Cellulose butyrate 24937-78-8, EVA 24937-79-9, Polyvinylidene fluoride 24980-41-4, Polycaprolactone 25014-41-9, Polyacrylonitrile 25038-54-4, Polycaprolactam, biological studies 25101-13-7, Ethylene-methyl methacrylate copolymer 25248-42-4, Polycaprolactone 25249-16-5, Poly(2-hydroxyethyl methacrylate) 26009-03-0, PolyGlycolic acid 26023-30-3, Poly[oxy(1-methyl-2-oxo-1,2-ethanediyl)] 26100-51-6, Poly(DL-lactic acid) 26124-68-5, PolyGlycolic acid 26161-42-2 26780-50-7, Glycolide-lactide copolymer 26811-96-1, Poly(L-lactic acid) 29223-92-5 31621-87-1, Polydioxanone 31852-84-3, Poly(trimethylene carbonate) 32131-17-2, Nylon 66, biological studies 50862-75-4, Poly(oxycarbonyloxy-1,3-propanediyl) 113883-69-5, Glycolic acid-trimethylene carbonate copolymer 128171-16-4, Hydroxybutyric acid-hydroxyvaleric acid copolymer
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medical devices and compns. for treating vulnerable plaque)

IT 57-13-6D, Urea, derivs. 60-54-8, Tetracycline 110-85-0D, Piperazine, derivs. 463-77-4D, Carbamic acid, derivs. 502-44-3D, Caprolactone, derivs. 564-25-0, Doxycycline 7440-66-6D, Zinc, chelates 10118-90-8, Minocycline 88828-25-5, CMT 8 130370-60-4, Batimastat **154039-60-8**, Marimastat
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medical devices and compns. for treating vulnerable plaque)

IT **9004-61-9, Hyaluronic acid**
RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medical devices and compns. for treating vulnerable plaque)

RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **154039-60-8**, Marimastat
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medical devices and compns. for treating vulnerable plaque)

RN 154039-60-8 HCAPLUS
CN Butanediamide, N4-[(1S)-2,2-dimethyl-1-[(methylamino)carbonyl]propyl]-N1,2-dihydroxy-3-(2-methylpropyl)-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:428944 HCAPLUS

DN 137:24315
TI Compound of hydroxamic acid derivative and **hyaluronic acid** for treatment of joint disease
IN Ikeya, Hitoshi; Morikawa, Tadashi; Takahashi, Koichi; Okamachi, Akira; Tamura, Tatsuya
PA Chugai Seiyaku Kabushiki Kaisha, Japan; Denki Kagaku Kogyo Kabushiki Kaisha
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
IC ICM C08B037-08
ICS A61K031-728; A61P019-02; A61P029-00
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002044218	A1	20020606	WO 2001-JP10493	20011130
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002018512	A5	20020611	AU 2002-18512	20011130
PRAI	JP 2000-363993	A	20001130		
	WO 2001-JP10493	W	20011130		

OS MARPAT 137:24315
GI



I

AB Disclosed is a compd. having MMP inhibitory activity which is a compd. of a hydroxamic acid deriv. I and **hyaluronic acid**, wherein R1 = H, OH, C1-8 alkyl, etc.; R2 = C1-8 alkyl, etc.; R3 = C1-8 alkyl, etc.; R4 = H, C1-4 alkyl; R5 = -R7-R8-R9- (R7 = C1-8 alkylene, R8 = methylene, imino, O, etc., and R9 = C1-10 alkylene, etc.); and R6 = H, C1-4 alkyl, provided that R1 and R3 in combination may form a ring. The compd. comprises a group I and any of **hyaluronic acid**, a deriv. thereof, and salts of these, the former being bonded to a hydroxyl group of the latter through a carbamate linkage. Sodium **hyaluronate** was reacted with N-hydroxy-5-norbornene-2,3-dicarboxyimide (HONB) and hydroxamic acid deriv. N'-(13-amino-4,7,10-trioxatridecanyl)-N-(3S-hydroxy-4-(N-(1-methoxy-1-methylethoxy)amino)-2R-isobutylsuccinyl)-L-tert-leucinamide. The obtained compd. showed excellent inhibitory effect on gelatinase A and stromelysin-1 in in vitro test.

ST **hyaluronate** hydroxamate deriv prepn matrix metalloproteinase inhibitor

IT Joint, anatomical
(disease; **hyaluronic acid** hydroxamate derivs. for treatment of joint disease)
IT Antiarthritics
Antirheumatic agents
(**hyaluronic acid** hydroxamate derivs. for treatment of joint disease)
IT Collagens, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**hyaluronic acid** hydroxamate derivs. for treatment of joint disease)
IT **434283-17-7DP**, compexes with **hyaluronic acid**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**hyaluronic acid** hydroxamate derivs. for treatment of joint disease)
IT 434283-18-8D, reaction products with **hyaluronate** derivs.
434283-19-9D, reaction products with **hyaluronate** derivs.
434283-20-2D, reaction products with **hyaluronate** derivs.
434283-21-3D, reaction products with **hyaluronate** derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**hyaluronic acid** hydroxamate derivs. for treatment of joint disease)
IT 79955-99-0, Stromelysin-1 141907-41-7, Matrix metalloproteinase 146480-35-5, Gelatinase A
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibition of; **hyaluronic acid** hydroxamate derivs. for treatment of joint disease)
IT 116-11-0 5470-11-1, Hydroxyammonium chloride **9067-32-7**, Sodium **hyaluronate** 21715-90-2, HONb 62965-35-9, N-(tert-Butoxycarbonyl)-L-tert-leucine 157518-70-2 220156-99-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of **hyaluronic acid** hydroxamate derivs. for treatment of joint disease)
IT 433708-29-3P 433708-31-7P 433708-33-9P 433708-35-1P
433708-37-3P 433708-39-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of **hyaluronic acid** hydroxamate derivs. for treatment of joint disease)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Chugai Pharmaceutical Co Ltd; EP 1082963 A 1999 HCAPLUS
(2) Chugai Pharmaceutical Co Ltd; WO 9959603 A 1999 HCAPLUS
(3) Shionogi & Co Ltd; WO 0046189 A 2000 HCAPLUS
IT **434283-17-7DP**, compexes with **hyaluronic acid**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**hyaluronic acid** hydroxamate derivs. for treatment of joint disease)
RN 434283-17-7 HCAPLUS
CN Carbamic acid, [3-[(18S,21R)-18-(1,1-dimethylethyl)-21-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-23-methyl-1,17,20-trioxo-6,9,12-trioxa-2,16,19-triazatetracos-1-yl]bicyclo[2.2.1]hept-5-en-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **434283-20-2D**, reaction products with **hyaluronate** derivs.
434283-21-3D, reaction products with **hyaluronate** derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**hyaluronic acid** hydroxamate derivs. for treatment of joint disease)

RN 434283-20-2 HCAPLUS

CN Carbamic acid, [3-[(18S,21R)-18-(1,1-dimethylethyl)-21-[2-(hydroxyamino)-2-oxoethyl]-23-methyl-1,17,20-trioxo-6,9,12-trioxa-2,16,19-triazatetracos-1-yl]bicyclo[2.2.1]hept-5-en-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 434283-21-3 HCAPLUS
CN Carbamic acid, [3-[(18S,21R)-18-(1,1-dimethylethyl)-21-[(1S)-2-(hydroxyamino)-1-methyl-2-oxoethyl]-23-methyl-1,17,20-trioxo-6,9,12-trioxa-2,16,19-triazatetracos-1-yl]bicyclo[2.2.1]hept-5-en-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **9067-32-7**, Sodium **hyaluronate**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of **hyaluronic acid** hydroxamate derivs. for treatment of joint disease)
RN 9067-32-7 HCAPLUS
CN Hyaluronic acid, sodium salt (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **433708-37-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of **hyaluronic acid** hydroxamate derivs. for treatment of joint disease)

RN 433708-37-3 HCAPLUS
CN 6,9,12-Trioxa-2,16,19-triazatetracosanoic acid, 18-(1,1-dimethylethyl)-21-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-23-methyl-17,20-dioxo-, phenylmethyl ester, (18S,21R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L12 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:545502 HCAPLUS
DN 135:117219
TI Hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms
IN Yu, Baofa
PA USA
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K033-40
ICS A61K031-06; A61K031-045; A61P035-00
CC 1-6 (Pharmacology)
Section cross-reference(s): 15
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001052868	A1	20010726	WO 2001-US1737	20010118
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002044919	A1	20020418		
PRAI	US 2000-177024P	P	20000119	US 2001-765060	20010117

AB Methods are provided for treating neoplasms, tumors and cancers, using one or more haptens and coagulation agents or treatments, alone or in combination with other anti-neoplastic agents or treatments. Also provided are combinations, and kits contg. the combinations for effecting the therapy.

ST hapten coagulation agent antineoplastic agent combination antitumor

IT Gene, animal
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(APC; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(B-lym; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(DCC; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Ki-ras; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Cytokines
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MBP (major basic protein); hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(N-myc; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(N-ras; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NF-1; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(RB1; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(TP53; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(WT-1; hapten-coagulation agent-antineoplastic agent combinations for

treating neoplasms)

IT Adrenal cortex
(adrenocortical suppressants; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Interleukin 1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(and anti-IL1 antibody; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Cytokines
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(and cytokine gene; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Chemokines
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(angiostatic chemokine gene; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene
Steroids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(angiostatic; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Nutrients
(anti-; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Antisense oligonucleotides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-oncogene; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Intestine, neoplasm
(anus, inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Antitumor agents
(anus; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Nerve
(auditory, cancer inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Biliary tract
(bile duct, neoplasm, inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Antitumor agents
(bladder carcinoma; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Antitumor agents
(bone; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Antitumor agents
(brain; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(c-Ha-ras; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(c-abl; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(c-erbA; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(c-erbB; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(c-myc; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(c-sis; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Ear
Heart
Oviduct
Pituitary gland
Tonsil
(cancer inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Bladder
Esophagus
Kidney, neoplasm
Lung, neoplasm
Mammary gland
Ovary, neoplasm
(carcinoma, inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Immunity
(cell-mediated; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(central nervous system; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Nervous system
(central, neoplasm, inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Uterus, neoplasm
(cervix, inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(cervix; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Intestine, neoplasm
(colon, inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(colon; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Human immunodeficiency virus
(conditionally replicating, vector; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Therapy
(cryothrapy and transpupillary thermotherapy; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Cytolysis
(cytolytic gene; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Basement membrane
(degrdn., inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(digestive tract; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Uterus, neoplasm
(endometrium, inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(endometrium; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Cytotoxic agents
(endothelial cell; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Blood vessel
(endothelium, endothelial cell proliferation inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(erbB2; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(esophagus carcinoma; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(esophagus; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ets; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Brucella melitensis
(ext.; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(eye; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fes; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fgr; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fms; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fos; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(fps; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Alkylating agents, biological
Angiogenesis inhibitors
Antitumor agents
Chelating agents

Corynebacterium parvum
Coupling agents
Drug delivery systems
Immunostimulants
Immunotherapy
Mycobacterium BCG
Newcastle disease virus
Oxidizing agents
Radiosensitizers, biological
Radiotherapy
Reducing agents
Retroviral vectors
Surgery
Virus vectors
(hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Haptens
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Alcohols, biological studies
Antibodies
Enzymes, biological studies
Hormones, animal, biological studies
Interleukin 12
Interleukin 2
Interleukin 4
Laminins
Natural products
Ovalbumin
Polysaccharides, biological studies
Protamines
Reporter gene
Retinoids
Thrombospondins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Antitumor agents
(head; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Liver, neoplasm
(hepatoma, inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Antitumor agents
(hepatoma; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Herb
(herbal ext.; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Human herpesvirus
(herpes simplex viral amplicon vector; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hit; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(hst; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Immunity
(humoral; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Adrenal gland, neoplasm
Bone, neoplasm
Brain, neoplasm
Cell migration
Eye, neoplasm
Kidney, neoplasm
Lung, neoplasm
Ovary, neoplasm
Pancreas, neoplasm
Skin, neoplasm
Stomach, neoplasm
Testis, neoplasm
Thyroid gland, neoplasm
Uterus, neoplasm
(inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Drug delivery systems
(injections; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(int-1; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(int2; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Proteins, specific or class
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(interferon .gamma.-inducible protein 10; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(jun; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Antitumor agents
(kidney carcinoma; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Antitumor agents
(kidney; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Antitumor agents
(larynx tumor inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Lasers
(laser coagulation; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Eye
(lid, cancer inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Antitumor agents
(lung carcinoma; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Antitumor agents
(lung non-small-cell carcinoma; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Antitumor agents
(lung; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(mammary gland carcinoma; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(mammary gland; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Jaw
(mandibula, cancer inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Jaw
(mandibula, condylar process, cancer inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mas; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Jaw
(maxilla, cancer inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(met; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mil; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mos; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(mouth; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(myb; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Pharynx
(nasopharynx, neoplasm, inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(nasopharynx; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(neck; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Digestive tract
Esophagus
Head
Mammary gland
Mouth
Neck, anatomical
Nose
Prostate gland
Salivary gland
Spinal cord
Urethra
(neoplasm, inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(neu; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Vibrio cholerae
(neuraminidase; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Lung, neoplasm
(non-small-cell carcinoma, inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Virus
(nonvirulant; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(oncogene, inhibitor; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(ovary carcinoma; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(ovary; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(p16; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(p21; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(p27; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(pancreas; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Salivary gland
(parotid, cancer inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(penis tumor inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Fibronectins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(peptides; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Microwave
(percutaneous microwave coagulation therapy; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Proteins, specific or class
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(placental proliferin-related protein; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Proliferation inhibition
(proliferation inhibitors, endothelial cell; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Proteins, specific or class
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(proliferin-related protein; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(prostate gland; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Denaturants
(protein denaturing agents; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Denaturation
(protein, agents for; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Necrosis
(radio-frequency-induced coagulation necrosis; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(raf; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ral; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Intestine, neoplasm
(rectum, inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(rectum; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(rel; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Eye
(retina, cancer inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ros; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ski; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(skin; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(small intestine; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Intestine, neoplasm
(small, inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(solid tumor; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents

(spinal cord; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(src; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Antitumor agents
(stomach; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(suicide gene; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Antitumor agents
(testis; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Antitumor agents
(thyroid; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(trk; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Larynx
Penis
(tumor inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Proteins, specific or class
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor suppressor protein; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Gene, animal
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tumor suppressor; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Vagina
(tumor, inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Antigens
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(tumor-assocd.; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Fibroblast growth factor receptors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(type 1, sol.; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Sound and Ultrasound
(ultrasonic therapy; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Antitumor agents
(urethra; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT Antitumor agents
(uterus; hapten-coagulation agent-antineoplastic agent combinations for

treating neoplasms)
IT Immunization
(vaccination; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(vaginal tumor inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Adenoviridae
Simian virus 40
Vaccinia virus
(vector; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Nerve
(vestibulocochlear, cancer inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Fluids
(vitreous; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Reproductive tract
(vulva, neoplasm, inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Antitumor agents
(vulva; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Gene, animal
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(yes; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha., antibody to; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Interferons
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.alpha.; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.v.beta.3, antibody to; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT Interferons
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.gamma.; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT 9001-67-6, Neuraminidase
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Vibrio cholera; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT 127464-60-2, Vascular endothelial growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antibody to, and VEGF inhibitors; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT 106096-93-9, Basic fibroblast growth factor
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antibody to; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)
IT 50-01-1, Guanidine hydrochloride 50-02-2, Dexamethasone 50-18-0,

Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone 52-67-5, D-Penicillamine 53-02-1, Tetrahydrocortisol 53-06-5, Cortisone 53-86-1, Indomethacin 54-05-7, Chloroquine 56-81-5, Glycerol, biological studies 57-13-6, Urea, biological studies 57-13-6D, Urea, derivs., biological studies 57-55-6, 1,2-Propanediol, biological studies 58-27-5, Menadione 59-05-2, Methotrexate 60-24-2, 2-Mercaptoethanol 60-34-4D, Methylhydrazine, derivs. 64-17-5, Ethyl alcohol, biological studies 67-56-1, Methyl alcohol, biological studies 67-63-0, Isopropyl alcohol, biological studies 67-66-3, Chloroform, biological studies 70-34-8, Dinitrofluorobenzene 71-23-8, n-Propyl alcohol, biological studies 71-36-3, n-Butyl alcohol, biological studies 71-41-0, n-Pentyl alcohol, biological studies 75-65-0, tert-Butyl alcohol, biological studies 75-85-4, tert-Pentyl alcohol 75-91-2, tert-Butyl hydroperoxide 78-83-1, Isobutyl alcohol, biological studies 78-92-2, sec-Butyl alcohol 88-89-1, Trinitrophenol 96-41-3, Cyclopentanol 104-54-1, Cinnamyl alcohol 107-18-6, Allyl alcohol, biological studies 107-21-1, 1,2-Ethanediol, biological studies 108-93-0, Cyclohexanol, biological studies 108-95-2, Phenol, biological studies 111-27-3, n-Hexyl alcohol, biological studies 111-70-6, n-Heptyl alcohol 111-87-5, n-Octyl alcohol, biological studies 112-30-1, n-Decyl alcohol 112-53-8, n-Dodecyl alcohol 112-72-1, n-Tetradecyl alcohol 112-92-5, n-Octadecyl alcohol 115-77-5, Pentaerythritol, biological studies 123-51-3, Isopentyl alcohol 128-08-5, N-Bromosuccinimide 128-53-0, N-Ethylmaleimide 137-32-6, Active-amyl alcohol 145-63-1, Suramin 147-94-4, AraC 151-51-9, Carbodiimide 152-58-9, Cortexolone 342-69-8, 6-Methylmercaptopurine riboside 446-86-6, Azathioprine 504-63-2, 1,3-Propanediol 517-28-2, Hematoxylin 520-85-4, Medroxyprogesterone 593-84-0, Guanidinium thiocyanate 994-36-5, Sodium citrate 1398-61-4, Chitin 4846-27-9 6117-91-5, Crotyl alcohol 7440-06-4D, Platinum, coordination complexes, biological studies 7585-39-9, .beta.-Cyclodextrin 7722-84-1, Hydrogen peroxide, biological studies 7790-28-5, Sodium periodate 8049-47-6, Pancreatin 9001-73-4, Papain 9002-62-4D, Prolactin, 16-kDa fragment, biological studies **9004-61-9**, **Hyaluronan** 9005-49-6, Heparin, biological studies 9012-72-0, Glucan 9025-39-2, Heparinase 10028-15-6, Ozone, biological studies 10102-43-9, Nitric oxide, biological studies 10118-90-8, Minocycline 10361-76-9, Potassium peroxymonosulfate 10465-78-8, Diamide 11103-57-4, vitamin A 11118-27-7, Gold chloride 14769-73-4, Levamisole 15307-86-5, Diclofenac 15663-27-1, Cisplatin 15687-27-1, Ibuprofen 15866-90-7, Metastat 22668-01-5, SR 2508 23214-92-8D, Doxorubicin, conjugates with adipic dihydrazide 25550-58-7, Dinitrophenol 27314-97-2, Tirapazamine 27591-97-5, Tilorone 33069-62-4, Paclitaxel 33507-63-0, Substance P 34031-32-8, Auranofin 36653-82-4, 1-Hexadecanol 36877-68-6D, Nitroimidazole, derivs. 36930-63-9 37270-94-3, platelet factor 4 39450-01-6 51110-01-1, Somatostatin 51592-06-4, Iodogen 59865-13-3, Cyclosporin A 73590-58-6, Omeprazole 75706-12-6, SU101 83150-76-9, Octreotide 83869-56-1, GM-CSF 84088-42-6, Linomide 86090-08-6, Angiostatin 105844-41-5, Plasminogen activator inhibitor 108121-76-2D, Anthracenedione, derivs. 124861-55-8 126857-36-1, O8, biological studies 129298-91-5, AGM-1470 130370-60-4, BB-94 134633-29-7, Tecogalan sodium 140207-93-8 140208-24-8, tissue inhibitor of metalloproteinase-1 145809-21-8, tissue inhibitor of metalloproteinase-3 148805-91-8 153851-75-3, Heptoxepane **154039-60-8**, BB-2516 166981-13-1, CT-2584 184110-80-3, GM 1474 188417-67-6, CM 101 203515-84-8 324740-00-3, Vitaxin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT 9040-48-6, Gelatinase 9055-65-6, prostaglandin synthase 79955-99-0, Stromelysin 1 141907-41-7, Matrix metalloproteinase

RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitor; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

IT 9001-99-4, RNase
RL: BSU (Biological study, unclassified); BIOL (Biological study) (placental RNase inhibitor; hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Battentier, E; FR 2505182 A 1982 HCAPLUS
(2) Berd, D; US 5290551 A 1994 HCAPLUS
(3) Cone, C; US 4724230 A 1988 HCAPLUS
(4) du Pont; EP 0378888 A 1990 HCAPLUS
(5) Roy, W; WO 0006143 A 2000 HCAPLUS
(6) Rubin, D; US 5005588 A 1991
(7) Rupchock, P; US 4447526 A 1984 HCAPLUS
(8) Zhang, M; Melanoma Research 1998, V8(6), P510 HCAPLUS

IT **9004-61-9, Hyaluronan 154039-60-8**, BB-2516
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms)

RN 9004-61-9 HCAPLUS
CN Hyaluronic acid (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 154039-60-8 HCAPLUS
CN Butanediamide, N4-[(1S)-2,2-dimethyl-1-[(methylamino)carbonyl]propyl]-N1,2-dihydroxy-3-(2-methylpropyl)-, (2S,3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2003 ACS
AN 1994:46 HCAPLUS
DN 120:46
TI A stromelysin assay for the assessment of metalloprotease inhibitors on human aggregated proteoglycan
AU Doughty, J. R.; Goldberg, R. L.; Ganu, V.; Melton, R. A.; Hu, S. I.; Di Pasquale, G.
CS Pharm. Div., CIBA-GEIGY Corp., Summit, NJ, 07901, USA
SO Agents and Actions (1993), 39(Spec. Conf. Issue), C151-C153
CODEN: AGACBH; ISSN: 0065-4299
DT Journal
LA English
CC 1-1 (Pharmacology)
AB Human proteoglycan was aggregated to an immobilized **hyaluronan** solid phase on a 96-well ELISA plate. This complex was then degraded by recombinant human stromelysin. The remaining proteoglycan fragments were detected using a monoclonal antibody probe directed against the chondroitin sulfate (CS) region of the core protein. Stromelysin degraded

the aggregate in a time and dose dependent manner as reflected by the loss of the CS epitope. Assay sensitivity was 0.125 U/well with total loss of the CS epitope occurring at 4 U/well. O-phenanthroline (IC50 = 52 .mu.M) and U24522 (IC50 = 9 .mu.M) inhibited degrdn., while phosphoramidon did not. Serine and cysteine protease inhibitors had no effect. A comparative anal. of this assay with a ref. method, substance P assay, gave similar inhibitor profiles. The use of aggregated human proteoglycan (native conformation) as a substrate, may better reflect how stromelysin inhibitors behave in the presence of complex substrates such as cartilage matrix.

ST stromelysin assay metalloprotease inhibitor aggregated proteoglycan

IT Inflammation inhibitors
(antiarthritics, metalloprotease inhibitors as, proteoglycan degrdn. inhibition as assay of)

IT Proteoglycans, biological studies
RL: PRP (Properties)
(chondroitin sulfate-contg., metalloprotease inhibitors prevention of degrdn. of, by stromelysin, antiarthritics assay by)

IT 79955-99-0, Stromelysin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, assay of antiarthritic activity of, proteoglycan degrdn. inhibition in)

IT 66-71-7, o-Phenanthroline **106314-87-8**, U24522
RL: ANST (Analytical study)
(proteoglycan degrdn. inhibition by, as metalloprotease inhibitor, antiarthritic activity in relation to)

IT 36357-77-4, Phosphoramidon
RL: ANST (Analytical study)
(proteoglycan degrdn. response to, as metalloprotease inhibitor, antiarthritic activity in relation to)

IT **106314-87-8**, U24522
RL: ANST (Analytical study)
(proteoglycan degrdn. inhibition by, as metalloprotease inhibitor, antiarthritic activity in relation to)

RN 106314-87-8 HCAPLUS

CN L-Phenylalaninamide, N-[2-[2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil reg
FILE 'REGISTRY' ENTERED AT 16:41:48 ON 27 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 26 JAN 2003 HIGHEST RN 481631-75-8

DICTIONARY FILE UPDATES: 26 JAN 2003 HIGHEST RN 481631-75-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d sta que l5
L3 STR



VAR G1=H/OH/AK
VAR G2=AK/16
NODE ATTRIBUTES:
CONNECT IS M1 RC AT 10
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L4 (2264)SEA FILE=REGISTRY SSS FUL L3
L5 629 SEA FILE=REGISTRY SUB=L4 CSS FUL L3

100.0% PROCESSED 2264 ITERATIONS
SEARCH TIME: 00.00.01 629 ANSWERS